Complete remission of ovarian cancer induced intractable malignant ascites with intraperitoneal bevacizumab. Immunological observations and a literature review

被引：40

作者：

Bellati, Filippo ^{[1
,2
,3
]}

Napoletano, Chiara ^{[2
]}

Ruscito, Ilary ^{[2
]}

Pastore, Maria ^{[3
]}

Pernice, Milena ^{[3
]}

Antonilli, Morena ^{[3
]}

Nuti, Marianna ^{[2
]}

Panici, Pierluigi Benedetti ^{[3
]}

机构：

[1] Univ Rome Sapienza, Dept Gynecol & Obstet, I-15500161 Rome, Italy

[2] Sapienza Univ, Dept Expt Med, Rome, Italy

[3] Sapienza Univ, Inst Obstet & Gynaecol, Rome, Italy

来源：

INVESTIGATIONAL NEW DRUGS | 2010年 / 28卷 / 06期

关键词：

Ascites; Bevacizumab; Intraperitoneal; Lymphocyte; Ovarian Cancer; REGULATORY T-CELLS; ENDOTHELIAL GROWTH-FACTOR; FALLOPIAN-TUBE CANCER; PHASE-II CONSORTIA; EPITHELIAL OVARIAN; RECURRENT OVARIAN; DEMONSTRATES ACTIVITY; MONOCLONAL-ANTIBODY; PLATINUM RESISTANCE; PRIMARY PERITONEAL;

D O I：

10.1007/s10637-009-9351-4

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Malignant ascites resistant to conventional drugs frequently affects ovarian cancer patients at the end of life. Here we report the case of a patient who benefited from complete resolution of ascites after low dose intraperitoneal administration of bevacizumab. Immunological analyses showed an initial increase in proportion and function of CD8(+) effector T cells and a reduction of circulating T(reg) cells. A review of the current literature regarding bevacizumab in ovarian cancer is reported. Bevacizumab has shown a high efficacy in the treatment of ovarian cancer. Intraperitoneal administration induces an immune activation and appears promising in the treatment of malignant ascites.

引用

页码：887 / 894

页数：8

共 51 条

[1] Malignant ascites: Past, present, and future [J].

Adam, RA ;

Adam, YG .

JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS, 2004, 198 (06) :999-1011

[2] Influence of bevacizumab, sunitinib and sorafenib as single agents or in combination on the inhibitory effects of VEGF on human dendritic cell differentiation from monocytes [J].

Alfaro, C. ;

Suarez, N. ;

Gonzalez, A. ;

Solano, S. ;

Erro, L. ;

Dubrot, J. ;

Palazon, A. ;

Hervas-Stubbs, S. ;

Gurpide, A. ;

Lopez-Picazo, J. M. ;

Grande-Pulido, E. ;

Melero, I. ;

Perez-Gracia, J. L. .

BRITISH JOURNAL OF CANCER, 2009, 100 (07) :1111-1119

[3] Intraperitoneal cisplatin and paclitaxel in ovarian cancer [J].

Armstrong, DK ;

Bundy, B ;

Wenzel, L ;

Huang, HQ ;

Baergen, R ;

Lele, S ;

Copeland, LJ ;

Walker, JL ;

Burger, RA .

NEW ENGLAND JOURNAL OF MEDICINE, 2006, 354 (01) :34-43

[4] Bevacizumab demonstrates activity in advanced refractory fallopian tube carcinoma [J].

Arora, N. ;

Tewari, D. ;

Cowan, C. ;

Saffari, B. ;

Monk, B. J. ;

Burger, R. A. .

INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2008, 18 (02) :369-U2

[5] Pattern and prognostic factors in patients with malignant ascites: a retrospective study [J].

Ayantunde, A. A. ;

Parsons, S. L. .

ANNALS OF ONCOLOGY, 2007, 18 (05) :945-949

[6] Combination targeted therapy with sorafenib and bevacizumab results in enhanced toxicity and antitumor activity [J].

Azad, Nilofer S. ;

Posadas, Edwin M. ;

Kwitkowski, Virginia E. ;

Steinberg, Seth M. ;

Jain, Lokesh ;

Annunziata, Christina M. ;

Minasian, Lori ;

Sarosy, Gisele ;

Kotz, Herbert L. ;

Premkumar, Ahalya ;

Cao, Liang ;

McNally, Deborah ;

Chow, Catherine ;

Chen, Helen X. ;

Wright, John J. ;

Kohn, Elise C. .

JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (22) :3709-3714

[7] Significant differences of lymphocytes isolated from ascites of patients with ovarian cancer compared to blood and tumor lymphocytes.: Association of CD3+CD56+ cells with platinum resistance [J].

Bamias, A. ;

Tsiatas, M. L. ;

Kafantari, E. ;

Liakou, C. ;

Rodolakis, A. ;

Voulgaris, Z. ;

Vlahos, G. ;

Papageorgiou, T. ;

Tsitsilonis, O. ;

Bamia, C. ;

Papatheodoridis, G. ;

Politi, Ek. ;

Archimandritis, A. ;

Antsaklis, A. ;

Dimopoulos, M. A. .

GYNECOLOGIC ONCOLOGY, 2007, 106 (01) :75-81

[8] Correlation of NK T-like CD3+CD56+ cells and CD4+CD25+(hi) regulatory T cells with VEGF and TNFα in ascites from advanced ovarian cancer:: Association with platinum resistance and prognosis in patients receiving first-line, platinum-based chemotherapy [J].

Bamias, Aristotelis ;

Koutsoukou, Vasiliki ;

Terpos, Evangelos ;

Tsiatas, Marinos L. ;

Liakos, Christina ;

Tsitsilonis, Ourania ;

Rodolakis, Alexandros ;

Voulgaris, Zannis ;

Vlahos, G. ;

Papageorgiou, Theocharis ;

Papatheodoridis, G. ;

Archimandritis, A. ;

Antsaklis, A. ;

Dilnopoulos, M. A. .

GYNECOLOGIC ONCOLOGY, 2008, 108 (02) :421-427

[9] Immunology of Gynecologic Neoplasms: Analysis of the Prognostic Significance of the Immune Status [J].

Bellati, F. ;

Visconti, V. ;

Napoletano, C. ;

Antonilli, M. ;

Frati, L. ;

Panici, P. Benedetti ;

Nuti, M. .

CURRENT CANCER DRUG TARGETS, 2009, 9 (04) :541-565

[10]

BEREK JS, 1983, OBSTET GYNECOL, V61, P189

← 1 2 3 4 5 6 →